Tetsuaki Hirase
Kobe, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes.
Journal: Journal of diabetes investigation
Published: May 26, 2025
Association Between Early Weight Loss and Metabolic Outcomes with Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J Post Hoc Analysis.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: May 14, 2025
Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: October 19, 2024
Trends of HbA1c and BMI in People with Type 2 Diabetes: A Japanese Claims-Based Study.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: December 18, 2023
Prevalence of Metabolic Syndrome in Patients with Type 2 Diabetes in Japan: A Retrospective Cross-Sectional Study.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: June 26, 2023
Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.
Journal: Diabetes, obesity & metabolism
Published: March 29, 2023
Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial.
Journal: Journal of cardiology
Published: November 17, 2022
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme).
Journal: Diabetes, obesity & metabolism
Published: October 20, 2022
Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA® Trial.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: May 19, 2020
Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: November 13, 2019
Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial.
Journal: Clinical therapeutics
Published: November 16, 2018
Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: January 08, 2018
Last Updated: 09/26/2026